Monoamine oxidase inhibition by L-deprenyl depends on both sex and route of administration in the rat.
The monoamine oxidase B (MAO-B) inhibitor L-deprenyl, widely used to treat Parkinson's disease, has frequently been studied in animal models. We have examined the effects of several variables on activity levels of MAO-A and B in rat brain and liver following chronic (3 wks) treatment with L-deprenyl. Significant effects were observed for sex (females showed lower overall MAO-B activity in the liver), dose (MAO-A and B inhibition increased with dose, with females exhibiting greater sensitivity), route of administration (subcutaneous injection was more efficient than oral dosing), and dosing interval (MAO-B was significantly inhibited when dosing interval was increased to as long as 168 hours). Our results thus indicate that the effectiveness of L-deprenyl in vivo is dependent on several factors and that these must be taken into account in studies involving the benefits or risks of this drug.
Murphy
M P
MP
Division of Life Sciences, University of Toronto, Scarborough College, Ontario, Canada.
Wu
P H
PH
Milgram
N W
NW
Ivy
G O
GO
D000284:Administration, Oral; D000818:Animals; D001921:Brain / Q000201:enzymology; D005260:Female; D007279:Injections, Subcutaneous; D007527:Isoenzymes / Q000378:metabolism*; D008099:Liver / Q000201:enzymology; D008297:Male; D008995:Monoamine Oxidase / Q000378:metabolism*; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology*; D051381:Rats; D011916:Rats, Inbred F344; D012642:Selegiline / Q000008:administration & dosage* / Q000494:pharmacology*; D012727:Sex Characteristics; D013270:Stomach / Q000187:drug effects
D007527:Isoenzymes; D008996:Monoamine Oxidase Inhibitors; D012642:Selegiline; D008995:Monoamine Oxidase